Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE

UCB Optimizes its Manufacturing Network

By Pharmaceutical Processing | December 15, 2010

UCB has agreed with Aesica, a leading pharmaceutical
manufacturer, that Aesica will acquire current UCB manufacturing businesses in Germany and Italy. The agreement is part of
UCB’s strategy to optimize its manufacturing network in line with the evolution
of its portfolio and includes the manufacturing sites of Monheim and Zwickau in Germany
and Pianezza in Italy.

The around 600 employees in the three affected sites will continue their
activity and be transferred to Aesica.

“UCB’s product portfolio has been changing significantly which reduced
UCB’s need for large manufacturing capacity for chemical entities, while
increasing its biotech requirements. This new partnership is part of UCB’s
strategy to optimize its manufacturing network while securing long-term supply
for our products and to ensure a long-term future to the sites and their employees,”
said Roch Doliveux, CEO of UCB.

Dr. Robert Hardy, Chief Executive Officer, Aesica says: “The acquisition
of the three manufacturing sites from UCB is strategically crucial for Aesica
as we extend and enhance our current offering and presence in Europe. 
We hope to fully utilize the expertise and knowledge across the current team at
UCB to achieve our vision of becoming the leading supplier of Formulated
Products and Actives Pharmaceutical Ingredients to the global pharmaceutical
and biotechnology industries.  In addition to welcoming the staff at the
three sites into the Aesica team, we look forward to working closely with the
wider team at UCB, as both companies see this as the first step in developing a
long-term strategic partnership.”

Subject to antitrust clearance, closing is expected for the first quarter of
2011. UCB’s financial outlook for 2010 remains unchanged.

 

 

Related Articles Read More >

GSK
GSK invests another $800M in Pennsylvania site expansions
This is a BD image of its major IV catheters manufacturing facility in Sandy, Utah, which the company said produces billions of molded components each year.
BD to invest billions in U.S. manufacturing
Diverse factory workers in yellow PPE suits checking production data with clipboard in modern industrial facility, Quality control inspector wearing masks and hairnets working in food or pharma plant
ISO 9001, 14001 and 45001 revisions: What changes and when to start
Artis BioSolutions announces new center of excellence in Spain
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE